The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells

Table 1 Summarizes results of MTT-tests in different rhabdoid tumor cell lines (A204, G401, BT16) treated with HDAC-inhibitors (SAHA, TSA, M344) cyclin D inhibitors (fenretinide, tamoxifen) as single compounds and in combinations of both classes of compounds

Cell line	Compound 1	Compound 2	IC 50 μM	m	CI	R²
A204	SAHA	---------------	24.72	0.6	---------------	0.72
A204	M344	---------------	128.76	0.57	---------------	0.67
A204	TSA	---------------	1.83	0.43	---------------	0.87
A204	Tam	---------------	2.67	0.5	---------------	0.86
A204	Fen	---------------	1.87	0.4	---------------	0.84
A204	SAHA	Tam	0.97	0.36	0.07	0.75
A204	SAHA	Fen	1.25	0.48	0.1	0.72
A204	M344	Tam	0.97	0.48	0.19	0.56
A204	M344	Fen	0.28	0.24	0.01	0.88
A204	TSA	Tam	0.16	0.2	0.08	0.77
A204	TSA	Fen	0.1	0.24	0.05	0.73
G401	SAHA	---------------	31.82	0.44	---------------	0.87
G401	Tam	---------------	3.13	0.53	---------------	0.89
G401	Fen	---------------	3.37	0.54	---------------	0.85
G401	SAHA	Tam	1.42	0.3	0.06	0.9
G401	SAHA	Fen	1.65	0.54	0.09	0.91
BT16	SAHA	---------------	8.39	0.64	---------------	0.93
BT16	Tam	---------------	2.09	0.75	---------------	0.9
BT16	Fen	---------------	2.74	0.5	---------------	0.91
BT16	SAHA	Tam	0.11	0.44	0.02	0.87
BT16	SAHA	Fen	0.43	0.52	0.06	0.86

ISSN: 1471-2407